ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 975,34
1,10%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. COMPASS Pathways PLC (CMPS)

  7. COMPASS Pathways PLC (CMPS) Actualités

CMPS

COMPASS Pathways (CMPS)

COMPASS Pathways PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CMPS
DateHeureSourceTitreSymboleSociété
26/06/202412h30GlobeNewswire Inc.Compass Pathways appoints Lori Englebert as Chief Commercial OfficerNASDAQ:CMPSCOMPASS Pathways PLC
22/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
09/05/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPSCOMPASS Pathways PLC
08/05/202412h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMPSCOMPASS Pathways PLC
08/05/202412h45GlobeNewswire Inc.Compass Pathways Announces First Quarter 2024 Financial Results and Business HighlightsNASDAQ:CMPSCOMPASS Pathways PLC
08/05/202412h30GlobeNewswire Inc.Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderNASDAQ:CMPSCOMPASS Pathways PLC
02/05/202412h30GlobeNewswire Inc.Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatmentNASDAQ:CMPSCOMPASS Pathways PLC
29/04/202412h30GlobeNewswire Inc.Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depressionNASDAQ:CMPSCOMPASS Pathways PLC
28/03/202413h00GlobeNewswire Inc.Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of DirectorsNASDAQ:CMPSCOMPASS Pathways PLC
05/03/202423h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
29/02/202413h00GlobeNewswire Inc.Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights NASDAQ:CMPSCOMPASS Pathways PLC
29/02/202412h59Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CMPSCOMPASS Pathways PLC
14/02/202422h08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CMPSCOMPASS Pathways PLC
16/01/202414h00GlobeNewswire Inc.Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approvedNASDAQ:CMPSCOMPASS Pathways PLC
05/01/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMPSCOMPASS Pathways PLC
05/01/202414h00GlobeNewswire Inc.Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreementNASDAQ:CMPSCOMPASS Pathways PLC
02/01/202423h20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CMPSCOMPASS Pathways PLC
19/12/202322h05GlobeNewswire Inc.Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorderNASDAQ:CMPSCOMPASS Pathways PLC
13/12/202323h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
07/12/202313h00GlobeNewswire Inc.Compass Pathways appoints Teri Loxam as Chief Financial OfficerNASDAQ:CMPSCOMPASS Pathways PLC
06/12/202322h00GlobeNewswire Inc.Study results of psilocybin treatment in bipolar II depression published in JAMA PsychiatryNASDAQ:CMPSCOMPASS Pathways PLC
15/11/202310h00GlobeNewswire Inc.Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research centerNASDAQ:CMPSCOMPASS Pathways PLC
02/11/202312h00GlobeNewswire Inc.COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:CMPSCOMPASS Pathways PLC
26/10/202314h00GlobeNewswire Inc.COMPASS Pathways announces CFO transitionNASDAQ:CMPSCOMPASS Pathways PLC
19/09/202315h14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CMPSCOMPASS Pathways PLC
19/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMPSCOMPASS Pathways PLC
18/09/202322h31GlobeNewswire Inc.COMPASS Pathways appoints Daphne Karydas to its Board of DirectorsNASDAQ:CMPSCOMPASS Pathways PLC
08/09/202323h17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CMPSCOMPASS Pathways PLC
06/09/202310h00GlobeNewswire Inc.COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depressionNASDAQ:CMPSCOMPASS Pathways PLC
25/08/202302h51Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CMPSCOMPASS Pathways PLC
 Showing the most relevant articles for your search:NASDAQ:CMPS

Dernières Valeurs Consultées

BIT
UB48JP
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés